Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Leerink Partners Raises Price target on Neurocrine Biosciences (NBIX) Following Positive KINECT3 Results
October 8, 2015 2:49 PM EDTLeerink Partners reiterated an Outperform rating on Neurocrine Bio. (NASDAQ: NBIX), and raised the price target to $71.00 (from $67.00), following positive KINECT3 results. Analyst Paul Matteis We sees the likelihood of the emergence of an unexpected long-term safety signal as very low, but still possible given the patient population under surveillance.
Matteis commented, "On the heels of positive... More
Neurocrine Bio (NBIX) PT Raised to $96 at Piper Jaffray
October 8, 2015 10:52 AM EDTPiper Jaffray analyst Charles C. Duncan reiterated an Overweight rating and boosted his price target on Neurocrine Bio. (NASDAQ: NBIX) to $96.00 (from $86.00).
Duncan commented, "Today Neurocrine announced positive Phase III results on '854 in Tardive Dyskinesia patients with an underlying psychiatric disorder. Although... More
Neurocrine Biosciences (NBIX) Announces Significant Data from NBI-98854 Kinect 3 in Lardive Dyskinesia
October 8, 2015 6:34 AM EDTNeurocrine Biosciences (NASDAQ: NBIX) announced that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying... More
